A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer’s Perspective
Mark Nuijten,1 Livia Dainelli,2 Bahareh Rasouli,3 Krysmaru Araujo Torres,4 Moreno Perugini,5 Agnieszka Marczewska2 1Health Economics and Valuation, A2M, Amsterdam, the Netherlands; 2Global Market Access & Pricing, Nestlé Health Science, Vevey, Switzerland; 3Institute of Environmental Medicine, K...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c45a67ae116d4a99ad091c7171d32529 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c45a67ae116d4a99ad091c7171d32529 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c45a67ae116d4a99ad091c7171d325292021-12-02T16:15:20ZA Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer’s Perspective1178-7007https://doaj.org/article/c45a67ae116d4a99ad091c7171d325292021-07-01T00:00:00Zhttps://www.dovepress.com/a-meal-replacement-program-for-the-treatment-of-obesity-a-cost-effecti-peer-reviewed-fulltext-article-DMSOhttps://doaj.org/toc/1178-7007Mark Nuijten,1 Livia Dainelli,2 Bahareh Rasouli,3 Krysmaru Araujo Torres,4 Moreno Perugini,5 Agnieszka Marczewska2 1Health Economics and Valuation, A2M, Amsterdam, the Netherlands; 2Global Market Access & Pricing, Nestlé Health Science, Vevey, Switzerland; 3Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 4Medical Affairs, US Nestlé Health Science, Bridgewater, MA, USA; 5Commercial and Medical Affairs, Pharmaceuticals, Nestlé Health Science, Bridgewater, MA, USACorrespondence: Mark Nuijten Email mark@a2m.nlBackground: Obesity is a disease associated with high direct medical costs and high indirect costs resulting from productivity loss. The high prevalence of obesity generates the need for payers to identify cost-effective weight loss approaches. Among various weight management techniques, the OPTI (Optifast®) program is a clinically recognised total meal replacement diet that can lead to significant weight loss and reduction in complications. This study’s objective is to assess OPTI program’s cost-effectiveness in Switzerland in comparison to “no intervention” and pharmacotherapy.Methods: An event-driven decision-analytic model was used to estimate the payer’s cost savings through the reimbursement of OPTI program over a 1-year period as well as a lifetime in Switzerland. The analysis was performed on a broad population of people with obesity with a body mass index (BMI) higher than 30 kg/m2 following the OPTI program vs two comparators (liraglutide and “no intervention”). The model incorporated a higher risk of complications due to an increased BMI and their related healthcare costs. Data sources included published literature, clinical trials, official Swiss price/tariff lists and national population statistics. The primary perspective was that of a Swiss payer. Scenario analyses – for example, for patients with existing complications (such as myocardial infarction, stroke, type 2 diabetes mellitus) or severe obesity – were conducted to test the robustness of the results.Results: The OPTI program results in cost savings of CHF 20,886 (€ 18,724) and CHF 15,382 (€ 13,790) per person compared with “no intervention” and liraglutide 3 mg, respectively. In addition, OPTI program led to 1.133 and 0.734 quality-adjusted life years (QALYs) gained respectively against its comparators. Scenario analyses showed similar outcomes with cost savings and QALYs gained.Conclusion: OPTI program is a dominant strategy compared to “no intervention” and liraglutide 3 mg as it leads to both cost savings and QALY gain. Therefore, reimbursing the OPTI program for patients with obesity would be cost-effective for Swiss payers.Keywords: obesity, cost-effectiveness, OPTI program, total meal replacementNuijten MDainelli LRasouli BAraujo Torres KPerugini MMarczewska ADove Medical Pressarticleobesitycost-effectivenessopti programtotal meal replacementSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 14, Pp 3147-3160 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
obesity cost-effectiveness opti program total meal replacement Specialties of internal medicine RC581-951 |
| spellingShingle |
obesity cost-effectiveness opti program total meal replacement Specialties of internal medicine RC581-951 Nuijten M Dainelli L Rasouli B Araujo Torres K Perugini M Marczewska A A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer’s Perspective |
| description |
Mark Nuijten,1 Livia Dainelli,2 Bahareh Rasouli,3 Krysmaru Araujo Torres,4 Moreno Perugini,5 Agnieszka Marczewska2 1Health Economics and Valuation, A2M, Amsterdam, the Netherlands; 2Global Market Access & Pricing, Nestlé Health Science, Vevey, Switzerland; 3Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 4Medical Affairs, US Nestlé Health Science, Bridgewater, MA, USA; 5Commercial and Medical Affairs, Pharmaceuticals, Nestlé Health Science, Bridgewater, MA, USACorrespondence: Mark Nuijten Email mark@a2m.nlBackground: Obesity is a disease associated with high direct medical costs and high indirect costs resulting from productivity loss. The high prevalence of obesity generates the need for payers to identify cost-effective weight loss approaches. Among various weight management techniques, the OPTI (Optifast®) program is a clinically recognised total meal replacement diet that can lead to significant weight loss and reduction in complications. This study’s objective is to assess OPTI program’s cost-effectiveness in Switzerland in comparison to “no intervention” and pharmacotherapy.Methods: An event-driven decision-analytic model was used to estimate the payer’s cost savings through the reimbursement of OPTI program over a 1-year period as well as a lifetime in Switzerland. The analysis was performed on a broad population of people with obesity with a body mass index (BMI) higher than 30 kg/m2 following the OPTI program vs two comparators (liraglutide and “no intervention”). The model incorporated a higher risk of complications due to an increased BMI and their related healthcare costs. Data sources included published literature, clinical trials, official Swiss price/tariff lists and national population statistics. The primary perspective was that of a Swiss payer. Scenario analyses – for example, for patients with existing complications (such as myocardial infarction, stroke, type 2 diabetes mellitus) or severe obesity – were conducted to test the robustness of the results.Results: The OPTI program results in cost savings of CHF 20,886 (€ 18,724) and CHF 15,382 (€ 13,790) per person compared with “no intervention” and liraglutide 3 mg, respectively. In addition, OPTI program led to 1.133 and 0.734 quality-adjusted life years (QALYs) gained respectively against its comparators. Scenario analyses showed similar outcomes with cost savings and QALYs gained.Conclusion: OPTI program is a dominant strategy compared to “no intervention” and liraglutide 3 mg as it leads to both cost savings and QALY gain. Therefore, reimbursing the OPTI program for patients with obesity would be cost-effective for Swiss payers.Keywords: obesity, cost-effectiveness, OPTI program, total meal replacement |
| format |
article |
| author |
Nuijten M Dainelli L Rasouli B Araujo Torres K Perugini M Marczewska A |
| author_facet |
Nuijten M Dainelli L Rasouli B Araujo Torres K Perugini M Marczewska A |
| author_sort |
Nuijten M |
| title |
A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer’s Perspective |
| title_short |
A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer’s Perspective |
| title_full |
A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer’s Perspective |
| title_fullStr |
A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer’s Perspective |
| title_full_unstemmed |
A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer’s Perspective |
| title_sort |
meal replacement program for the treatment of obesity: a cost-effectiveness analysis from the swiss payer’s perspective |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/c45a67ae116d4a99ad091c7171d32529 |
| work_keys_str_mv |
AT nuijtenm amealreplacementprogramforthetreatmentofobesityacosteffectivenessanalysisfromtheswisspayerrsquosperspective AT dainellil amealreplacementprogramforthetreatmentofobesityacosteffectivenessanalysisfromtheswisspayerrsquosperspective AT rasoulib amealreplacementprogramforthetreatmentofobesityacosteffectivenessanalysisfromtheswisspayerrsquosperspective AT araujotorresk amealreplacementprogramforthetreatmentofobesityacosteffectivenessanalysisfromtheswisspayerrsquosperspective AT peruginim amealreplacementprogramforthetreatmentofobesityacosteffectivenessanalysisfromtheswisspayerrsquosperspective AT marczewskaa amealreplacementprogramforthetreatmentofobesityacosteffectivenessanalysisfromtheswisspayerrsquosperspective AT nuijtenm mealreplacementprogramforthetreatmentofobesityacosteffectivenessanalysisfromtheswisspayerrsquosperspective AT dainellil mealreplacementprogramforthetreatmentofobesityacosteffectivenessanalysisfromtheswisspayerrsquosperspective AT rasoulib mealreplacementprogramforthetreatmentofobesityacosteffectivenessanalysisfromtheswisspayerrsquosperspective AT araujotorresk mealreplacementprogramforthetreatmentofobesityacosteffectivenessanalysisfromtheswisspayerrsquosperspective AT peruginim mealreplacementprogramforthetreatmentofobesityacosteffectivenessanalysisfromtheswisspayerrsquosperspective AT marczewskaa mealreplacementprogramforthetreatmentofobesityacosteffectivenessanalysisfromtheswisspayerrsquosperspective |
| _version_ |
1718384317484236800 |